⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386054 | 1.00 | — | — | |
| SCHEMBL8915740 | 0.69 | — | — | |
| SCHEMBL19667940 | 0.69 | — | — | |
| SCHEMBL23612 | 0.69 | — | — | |
| SCHEMBL23611 | 0.69 | — | — | |
| SCHEMBL487128 | 0.69 | — | — | |
| SCHEMBL15739022 | 0.67 | — | — | |
| SCHEMBL1245306 | 0.67 | — | — | |
| SCHEMBL12143376 | 0.67 | — | — | |
| SCHEMBL2102369 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123285-A1 | Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-11-25 | — | — | EP | disclosed |